Tempest Therapeutics Shares Up 19% Premarket. A Press Release Earlier Announced A Presentation On Its Liver Cancer Treatment At ASCO Annual Meeting 2024

Tempest Therapeutics, Inc. - Common Stock -1.24%

Tempest Therapeutics, Inc. - Common Stock

TPST

3.18

-1.24%

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics, today announced its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The company presented compelling data highlighting the efficacy and safety of its lead candidate, TPST-1120, a first-in-class PPARα antagonist, in the treatment of liver cancer and other malignancies.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via